Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 22:6:21700.
doi: 10.1038/srep21700.

Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics

Affiliations

Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics

Antoine Blin et al. Sci Rep. .

Abstract

We present a new, rapid method for producing blood platelets in vitro from cultured megakaryocytes based on a microfluidic device. This device consists in a wide array of VWF-coated micropillars. Such pillars act as anchors on megakaryocytes, allowing them to remain trapped in the device and subjected to hydrodynamic shear. The combined effect of anchoring and shear induces the elongation of megakaryocytes and finally their rupture into platelets and proplatelets. This process was observed with megakaryocytes from different origins and found to be robust. This original bioreactor design allows to process megakaryocytes at high throughput (millions per hour). Since platelets are produced in such a large amount, their extensive biological characterisation is possible and shows that platelets produced in this bioreactor are functional.

PubMed Disclaimer

Conflict of interest statement

PlatOD, ESPCI INNOV, and the authors (A.B., A.L.G., A.M., S.P.-C., D.B. and M.R.) have a patent related to this work: “Fluidic device for producing platelets” (International Publication Number WO2015/075030 A1).

Figures

Figure 1
Figure 1. Design and principle of the experiment.
(a) Sketch of the experimental setup, including a container for cell suspension placed on an orbital mixer (i) to keep the cell concentration uniform, a peristaltic pump (ii), the microfluidic production device (iii), and tubing. The microfuidic device consists in a large entrance compartment, distributing the suspension among sixteen straight channels, whose serpentine shape allows the design to fit in a single glass slide. Each of these channels is formula image wide, formula image deep and formula image long. The dark blue region corresponds to the pillar forests that cover the straight part of the channels, while the U-turns are devoid of obstacles. (b) Pillars are arranged on a tilted hexagonal lattice. The angle between the main axis of the channel and that of the lattice is fixed to 10° in order to ensure that each cell encounters at least one pillar. The streamlines are illustrated with black lines and MKs with orange spheres. (c) Top view of the micro pillar array before cell perfusion and after 60 minutes perfusion. The capture process of cells at intermediate times will be described in Fig. 2. Scale bar, 100 formula imagem.
Figure 2
Figure 2. Capture and elongation of MKs on pillars.
(a) Side view representing the possible behaviours of cells in the chip: advection, translocation along the smooth surface of the channel, translocation along the sides of pillars, and capture followed by elongation. (b) Chronophotography of a MK capture: The advected MK is captured at formula image then translocates around a pillar. In advection it takes 3 ms for the MK to move 3 times its diameter, while 1.8 s are necessary to roll over the same distance by translocation. Scale bar, 20 formula imagem. (c) Top view of a MK elongation. The montage starts at −2 s, before the MK is captured by the left pillar. Scale bar, 20 formula imagem. (d) Surface density of captured MKs as a function of time during a perfusion of 6,7 ml at 200 000 MK/mL suspension through 1 chip, measured at different positions: formula image mm (formula image), formula image mm formula image, formula image mm formula image, formula image mm formula image, formula image mm (formula image). Counts were performed by two experimentalists and represented as (mean ± SD). (e) Surface density of elongated MKs as a function of time for the same conditions.
Figure 3
Figure 3. Elongation and rupture of MKs.
(a) Time lapse observation of a single MK (formula image). The origin of time is defined as the moment when the circulating MK is captured by a pillar. The first rupture occurs at t = 27 min, when a portion of string bearing 6 beads detaches from the rest of the cell. Other similar events occur at later times, involving one (t = 29 or 31 min) or several (t = 46 min) beads. Scale bar, 20 formula imagem. (b) Length of a megakaryocyte (n = 1). Stars (*) indicate fragmentation and numbers indicate different phases of the elongation process: (1) reorganization of proplatelets, (2) anchoring to a 2nd pillar, (3) dissociation from 1st pillar, (4) reorganization of proplatelets, (5) untangling of megakaryocyte segments (6) retraction of the residual chain. The time t = 0 min corresponds to the megakaryocyte anchorage to the first pillar. The sequence of pictures presented in panel (a) corresponds to snapshots taken between times depicted by arrows 3 and 5. The data are extracted from video 3.
Figure 4
Figure 4. Counts of MK loss and produced platelets in the microfluidic device and in the control sample.
(a) Variation of the number of MKs in the reservoir during a 2 h perfusion (20 mL, 5 chips). (b) Variation of the number of platelet-like particles formula image in the reservoir during a 2 h perfusion (20 mL, 5 chips). (c) Influence of the suspension concentration formula image on the number formula image of released platelet-like-particles during a 2 h perfusion with a small volume of culture (6.7 mL). The curve can be fitted with a linear law (slope formula image, correlation coefficient formula image).
Figure 5
Figure 5. Characterisation of platelet morphology in samples collected at the exit of the microfluidic device and in the control sample.
(a) Two-color flow cytometry analysis of platelets receptors, indicating the population of CD41+/CD42b+ platelets. (b) Single colour flow cytometry analysis of platelet receptor density, indicating the number of CD61, CD42b and CD49b receptors on the surface of platelets (n = 3). (c) Indirect immunofluorescence labelling with an anti-formula image-tubulin antibody, revealed by a secondary AlexaFluor488 goat anti-mouse antibody and AlexaFluor546 phalloidin for F-actin staining is performed in the absence (top panel) or presence (bottom panel) of thrombin. Circular tubulin staining, characteristic of unactivated platelets is seen in the samples collected at the exit of the fluidic device (top left), whereas larger fragments without circular tubulin staining are recovered in samples collected from the control (top right). Actin stress fibres (small arrow, full arrow indicate a filopod and dotted arrow a lamellipod) characteristic of activated platelets are seen in the samples collected at the exit of the fluidic device (bottom left), whereas larger elements without organised stress fibres staining are recovered in samples collected from the control (bottom right). Platelets are adherent to fibrinogen. Scale bar 5 formula imagem. (d) Electron microscopy observations of platelets on BSA or fibrinogen coated surface, upon TRAP activation. Discoid round platelets are indicated with full white arrows and pseudopods with dotted arrows. Scale bar 5 formula imagem.
Figure 6
Figure 6. Characterisation of platelet activation.
(a) Two-colour flow cytometry analysis of platelet receptors without or with activation with TRAP. Dot plots within the platelet gate indicate the population of PAC1 positive, CD42b+ platelets in the non stimulated (upper panels) and TRAP stimulated samples (lower panels) produced in the microfluidic device (left panels) vs control (right panels). (b) Quantification corresponding to the results presented in panel (a) (mean values for 4 independent experiments). (c) Aggregation in the presence of fibrinogen and CaCl2. Platelet aggregates are observed before (upper panels) or after (lower panels) activation with TRAP. The black arrow indicates a large aggregate visible in the sample collected at the exit of the fluidic device (lower left panel). Fragments recovered in the control samples do not aggregate in the presence of the agonist peptide (lower right panel). The scale bar represents 10 formula imagem.

Similar articles

Cited by

References

    1. Doshi N. et al. Platelet mimetic particles for targeting thrombi in flowing blood. Adv. Mater. 24, 3864–3869 10.1002/adma.201200607 (2012). - DOI - PMC - PubMed
    1. Takayama N. et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 111, 5298–5306 10.1182/blood-2007-10-117622 (2008). - DOI - PubMed
    1. Nakagawa Y. et al. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. Exp. Hematol. 41, 742–748 10.1016/j.exphem.2013.04.007 (2013). - DOI - PubMed
    1. Feng Q. et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports 3, 817–831 10.1016/j.stemcr.2014.09.010 (2014). - DOI - PMC - PubMed
    1. Cid J. & Lozano M. Platelet dose for prophylactic platelet transfusions. Expert Rev. Hematol. 3, 397–400 10.1586/ehm.10.36 (2010). - DOI - PubMed

Publication types

MeSH terms